ENDP : Analysis & Opinions
June 24, 2013Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
November 7, 2012Can Endo reestablish itself as a quality healthcare name?
January 18, 2012Salix is a great candidate for growth investors.
September 21, 2011Endo and Forest have problems; however, the valuations seem excessively low.